Dr Selwyn Ho is a seasoned healthcare executive, with over 25 years of international experience spanning Europe, the US and Asia. He has held senior leadership roles in both private and publicly traded biotech and pharmaceutical companies, with a focus on inflammation and immunology. Dr Ho became CEO of Medigene in July 2022, after serving as chief business officer at Connect Biopharma and executive-in-residence at New Rhein Healthcare Investors. He holds a medical degree (MB BS) and a BSc in pharmacology from Imperial College London, alongside post-graduate qualifications in pharmaceutical medicine from the Royal College of Physicians, UK.